HELP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cybin Inc (HELP) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has potential catalysts in the future, such as pipeline developments and CEO appointment, the current financial performance, lack of significant trading trends, and neutral technical indicators suggest that it is better to wait for clearer signals or stronger fundamentals before investing.
The MACD histogram is positive at 0.155 but contracting, indicating weakening momentum. RSI is neutral at 65.597, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 4.893, with resistance at 5.336 and support at 4.45. Overall, technical indicators suggest a neutral trend with no strong buy or sell signals.
Potential catalysts include the success of HLP003 in Phase III trials for adjunct major depressive disorder, which could lead to a significant share price rally. Additionally, Phase II data for HLP004 and the appointment of a CEO are expected to act as positive drivers.
These weak financials could deter long-term investors. Additionally, there is no recent news or significant insider/hedge fund activity to support a bullish case.
In Q3 2026, the company reported no revenue growth (0% YoY), a net loss of -$42.67M (up 465.96% YoY), and an EPS of -1 (up 163.16% YoY). While the EPS and net income have improved YoY, the company remains unprofitable with no revenue generation.
Jefferies analyst Andrew Tsai initiated coverage with a Buy rating and a $22 price target, citing potential catalysts in 2026. However, these catalysts are long-term and contingent on successful trial results and corporate developments.
